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Increasing evidence links proteins of the S100 family to the pathogenesis of Alzheimer’s
disease (AD). S100 proteins are EF-hand calcium-binding proteins with intra- and
extracellular functions related to regulation of proliferation, differentiation, apoptosis, and
trace metal homeostasis, and are important modulators of inflammatory responses.
For example, S100A6, S100A8, and S100B expression levels were found increased
in inflammatory diseases, but also neurodegenerative disorders, and S100A8/A9
complexes may provide a mechanistic link between amyloid-beta (Aβ) plaque formation
and neuroinflammation. On the other hand, S100B, a proinflammatory protein that is
chronically up-regulated in AD and whose elevation precedes plaque formation, was
recently shown to suppress Aβ aggregation. Here, we report expression of S100A6 and
S100B in astrocytes and less so in neurons, and low level of expression of S100A8 in
both neurons and glial cells in vitro. In vivo, S100A8 expression is almost absent in the
brain of aged wildtype mice, while S100A6 and S100B are expressed in all brain regions
and most prominently in the cortex and cerebellum. S100B seems to be enriched in
Purkinje cells of the cerebellum. In contrast, in the brain of APP23 mice, a mouse model
for Alzheimer’s disease, S100B, S100A6, and S100A8 show co-localization with Aβ
plaques, compatible with astrocyte activation, and the expression level of S100A8 is
increased in neural cells. While S100A6 and S100B are enriched in the periphery of
plaques where less fibrillar Aβ is found, S100A8 is more intense within the center of the
inclusion. In vitro assays show that, similarly to S100B, S100A6, and S100A8 also delay
Aβ aggregation suggesting a regulatory action over protein aggregation. We posit that
elevated expression levels and overlapping spatial distribution of brain S100 proteins
and plaques translates functional relationships between these inflammatory mediators
and AD pathophysiology processes that uncover important molecular mechanisms
linking the aggregation and neuroinflammation cascades.
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INTRODUCTION
Alzheimer’s disease (AD) is a common form of dementia,
resulting in a progressive decline of cognitive functions. The
pathological hallmarks include the presence of extracellular
senile plaques and intracellular neurofibrillary tangles. Senile
plaques are formed by aggregates of the amyloid-β (Aβ)
peptide that result from cleavage of the Amyloid Precursor
Protein (APP) through beta and gamma secretases, and a
pathological cascade of aggregation steps of monomeric Aβ
forming oligomers and finally fibrils (Masters et al., 2015). An
increased neuroinflammatory response has been observed in AD,
mediated by microglia and reactive astrocytes in the vicinity
of senile plaques. There, Aβ induces the chronic expression
and secretion of cytokines and chemokines – the so called
alarmins or danger associated molecular patterns (DAMPS) –
enhancing Aβ generation and possibly loss of synapses and
neurons (Venegas and Heneka, 2017). Among these alarmins
are S100, which are small EF-hand Ca2+-binding proteins
whose multiple functions are tied to expression levels and
intra- or extracellular localization (Heizmann et al., 2002;
Donato et al., 2009, 2013).
Understanding the physiology of S100 proteins in the
context of their concentration – dependent activities and the
investigation of the transition between their trophic roles (at
nanomolar intracellular levels) and deleterious pro-inflammatory
activities (at micromolar extracellular levels) is particularly
challenging in the context of AD pathophysiology, as it can open
new therapeutic opportunities [recently reviewed by Cristóvão
and Gomes (2019)]. S100B, S100A8, and S100A6 are among the
most prominent brain expressed S100 proteins, which are all
upregulated by aging and neuronal damage. These proteins also
share the ability to bind Zn2+/Cu2+ in sites secondary to those
of Ca2+-binding in the EF-hand motifs. This is an interesting
characteristic considering that dyshomeostasis of neurometals is
a well-established feature across neurodegenerative disorders and
in particular in AD (Leal et al., 2012; Barnham and Bush, 2014;
Cristovao et al., 2016).
S100B is one of the most abundant proteins in the brain
(0.5%) and is constitutively produced by astrocytes at low levels.
Brain injury and neurodegeneration result in astrocyte activation
and increased expression of S100B, with its extracellular release
and engagement of RAGE-mediated signaling and microglial
activation (Leclerc et al., 2010). Several evidences implicate
S100B in AD pathogenesis: it is systematically elevated in AD
patients and animal models (Sheng et al., 1994; Van Eldik and
Griffin, 1994; Peskind et al., 2001), it is present in elevated
amounts in astrocytes surrounding neuritic plaques preceding
their appearance (Sheng et al., 2000) and is suggested to regulate
plaque formation. Knockout of S100B in the PS/APP AD mouse
model selectively decreases plaque load in the cortical region
(Roltsch et al., 2010) and its overexpression increases Aβ levels
and deposits at early stages (Mori et al., 2010). While elevated
levels of extracellular S100B trigger AD aggravating roles as
a pro-inflammatory enhancer, novel protective functions for
S100B at lower levels and early disease stages are emerging.
Recently we have established that S100B is a regulator of
elevated zinc levels in the brain and that this metal-buffering
activity is tied to a neuroprotective role, through an indirect
effect on calcium levels and in inhibition of excitotoxicity
(Hagmeyer et al., 2017). Also, we have recently reported a
calcium-tuned interaction between S100B and Aβ42 monomers,
oligomers, and fibrils that suppresses Aβ42 aggregation and
mitigates its cellular toxicity (Cristóvão et al., 2018). S100A6
is also upregulated in AD patients as well as in AD model
mice (Boom et al., 2004; Wirths et al., 2010; Weissmann et al.,
2016). The protein is found in clusters in astrocyte-positive
regions within senile plaques. Its high affinity zinc binding
properties led to the suggestion that it may play a role in the
regulation of the homeostasis of this metal ion in AD (Boom
et al., 2004). Interestingly, a zinc sequestering effect similar
to that reported for S100B was recently elucidated: exogenous
S100A6 protected cultured cells against Zn2+ toxicity and in
APP/PS1 transgenic mice, increased S100A6 levels correlated
with disaggregation of Aβ and decrease in plaque load (Zhi-
Ying et al., 2019). Finally, S100A8 is also implicated in AD
and its levels correlate with those of Aβ, being elevated
in the hippocampus of Tg2576 and TgAPParc AD model
mice (Lodeiro et al., 2017). Reciprocally, exposure of SH-
SY5Y neuroblastoma cells to recombinant S100A8 increased
Aβ42 and decreased Aβ40 production (Lodeiro et al., 2017).
Studies in Tg2576 and TgAPParc AD mice brains indicate the
presence of S100A8 inclusions distinct from corpora amylacea,
that are formed independently of Aβ plaques (Lodeiro et al.,
2017), a feature which is likely tied to the self-assembly
propensity of the S100 family members (Fritz et al., 2010;
Carvalho et al., 2013a,b).
MATERIALS AND METHODS
Materials
Primary antibodies were purchased from Sigma Aldrich
(Map2, S100B), Novus Biologicals [S100A8 (calgranulin
A)], Abcam (GFAP, S100B, S100A6), and Covance (β-III
Tubulin). Secondary antibodies Alexa488 and Alexa568
were purchased from Life Technologies. Secondary
HRP antibodies were purchased from DAKO. Unless
otherwise indicated, all other chemicals were obtained
from Sigma-Aldrich.
Protein Expression and Purification
Recombinant Aβ42 was expressed in Escherichia coli and
purified as described previously (Botelho et al., 2012). The
human Aβ42 expression plasmid was a gift from J. Presto
(Karolinska Institute, Sweden). To obtain the monomeric
form, 1 mg of Aβ42 was dissolved in 7 M guanidine
hydrochloride and eluted in a Superdex S75 (GE Healthcare)
with 50 mM Hepes (pH 7.4). Low-bind tubes (Axygen
Scientific, Corning) were used in all procedures employing
Aβ42. Human S100B, S100A6, and S100A8 were expressed in
E. coli BL21(DE3) and purified to homogeneity using previously
established protocols and quantitated using reported extinction
coefficients (Botelho et al., 2012; Brophy et al., 2012). Apo
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S100B, S100A6, and S100A8 were prepared by incubation
at 37◦C for 2 h with a 300-fold excess of dithiothreitol
(DTT) and 0.5 mM EDTA and eluted in a Superdex S75
(GE Healthcare). To remove contaminant trace metals all
solutions were passed through Chelex resin (Bio-Rad). S100
protein solutions were prepared and stored in 50 mM Tris–
HCl pH 7.4.
Aβ42 Aggregation Kinetics
Aβ42 aggregation kinetics was investigated by monitoring the
fluorescence increase of the amyloid-sensitive dye Thioflavin-T
(ThT) (Gade Malmos et al., 2017; Cristóvão et al., 2019) as a
function of time in a plate reader (FLUOstar OPTIMA, BMG
Labtech) using a 440 nm excitation filter and a 480 nm emission
filter. Fluorescence was recorded using bottom optics in 96-well
polyethylene glycol-coated black polystyrene plates with a clear
bottom (Corning, 3881). Briefly, Aβ42 monomer was isolated
by gel filtration (Tricorn Superdex75 column, GE Healthcare) in
50 mM Hepes (pH 7.4) immediately prior to experiments and
diluted in the same buffer with 1.1 mM CaCl2. ThT (10 µM) was
added to each condition. Monomeric Aβ42 (5 µM) was used in
aggregation assays at 37◦C, without agitation with fluorescence
read every 400 s. For testing the effects of S100A6 and S100A8,
the proteins were added to the reaction media at 15 µM each.
S100B, whose effects on Aβ42 aggregation had been previously
reported (Cristóvão et al., 2018), was tested under identical assay
conditions as a comparison and control. Appropriate controls
in the absence of Aβ42 did not reveal significant variations
on ThT intensity due to S100 proteins alone. Triplicates were
routinely performed for all assays. Data analysis was carried
out using the AmyloFit platform, which implements the master
equations derived from basin-hopping algorithm that describe
the evolution of total fibril mass in the presence of primary
and secondary nucleation events, and from which microscopic
processes and reaction rates can be determined from global fitting
(Meisl et al., 2016). The kinetic traces were fitted using the
secondary nucleation model. The normalized intensity curves
and corresponding fits were extracted from the platform and
presented as normalized intensities representing fibrillar mass
fraction, from which the reaction half times (t1/2) were estimated
(Arosio et al., 2015).
Hippocampal Culture From Rat Brain
Pregnant rats were purchased from Janvier Labs. The preparation
of hippocampal cultures was performed as described before
(Grabrucker et al., 2009) from rat (embryonic day-18; E18).
After preparation the hippocampal neurons were seeded on
poly-l-lysine (0.1 mg/ml; Sigma-Aldrich) glass coverslips in a 24
well plate at a density of 3 × 104 cells/well. Cells were grown
in NeurobasalTM medium (Life Technologies), complemented
with B27 supplement (Life Technologies), 0.5 mM L-Glutamine
(Life Technologies) and 100 U/ml penicillin/streptomycin (Life
Technologies) and maintained at 37◦C in 5% CO2.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde (PFA)/4%
sucrose/PBS at 4◦C for 20 min. After washing 2× 5 min
with 1× PBS with 0.2% Triton X-100 at RT, blocking was
performed with 10% FBS in 1× PBS at RT for 1 h, followed
by the primary antibody for 2 h at RT. After a 3× 5 min
washing-step with 1× PBS, incubation with the secondary
Alexa488 and/or Alexa568 antibody followed for 1 h at RT.
The cells were washed again in 1× PBS for 10 min and cell
nuclei stained with DAPI for 5 min. After washing with aqua
bidest., coverslips were mounted using VectaMount (Vector
Labs). Fluorescence images were obtained using an upright
Axioscope microscope equipped with a Zeiss CCD camera
(16 bits; 1280 × 1024 ppi) using Axiovision software (Zeiss)
and ImageJ 1.51j.
Animals
Three and fifteen months-old male mice, Mus musculus, strain
C57BL/6 and APP23 (maintained on the same background) were
used. The animals were housed in plastic cages with stainless
steel mesh lids under the standard laboratory condition with
temperature 22–24◦C, food and water available ad libitum,
humidity 55% ±10% and 12/12 h light/dark cycle (lights
on at 7 AM).
Gene Expression Analysis
RNA was extracted using the Qiagen RNeasy lipid tissue
kit according to the manufacturer’s instructions. RNA
concentrations were measured using a NanoDrop 2000 (Thermo
Fisher Scientific). First strand synthesis and quantitative
real-time-PCR amplification were performed in a one-step,
single-tube format using the Rotor-Gene SYBR R© Green RT-PCR
kit from Qiagen according to the manufacturer’s protocol
in a total volume of 20 µl and gene specific QuantiTect
Primer Assays (Qiagen). Thermal cycling and fluorescent
detection were performed using the Rotor-Gene Q real-time
PCR machine (model 2-Plex HRM) (Qiagen). Resulting data
were analyzed using the HMBS gene as an internal standard
to normalize transcript levels. All quantitative real-time
PCR reactions were run in technical triplicates and mean
cycle threshold (ct) -values for each reaction were taken
into account for calculations. Ct values were calculated by
the Rotor-Gene Q Software (version 2.0.2) and transformed
into virtual mRNA levels according to the formula: virtual
mRNA level = 10 × [ct(target) − ct(standard)]/slope of
standard curve.
Histochemistry
Brain sections (14 µm thickness) were prepared from fresh
snap-frozen brains using a cryostat (Leica CM 3050S) with the
knife set at −23◦C. Three sections of the brain of the same
animal were collected on one microscope slide. For staining,
the slices were thawed for 20 min at RT, fixed with PFA/4%
Sucrose for 30 min at RT. After washing 10 min with 1× PBS,
incubation with Triton 0.2% in 1× PBS for 2 h at RT was
followed by incubation with Triton 0.05% for 10 min at RT.
The slides were covered with Blocking Solution (BS)(10% FCS
in 1× PBS) for 2 h at RT. The primary antibody was diluted
in BS and applied over-night at 4◦C. Subsequently, incubation
for 3× 10 min with Triton 0.05% at RT was followed by
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incubation with the secondary antibody coupled to Alexa488 or
Alexa568, diluted 1:500 in BS, at 37◦C for 1.5 h. After a 3×
15 min washing-step with Triton 0.05% and 1× 5 min with
1× PBS, cell nuclei were counterstained with DAPI and after
the last washing step with 1× PBS for 5 min, cover slips were
mounted using VectaMount. Zinpyr-1 staining was performed
at a final concentration of 10 µM and incubation time of 1 h at
RT. Subsequently, the sections were counterstained with DAPI.
Images were taken with a Zeiss LSM710 confocal microscope.
For image analysis, center and border zone of plaques were
determined using ImageJ. Zinpyr1 signal intensity was measured
of 50 plaques using the “plot profile” function along the diameter
of a plaque crossing the center. A clear difference between
center and border zone in Zinpyr1 fluorescence intensity can be
observed with the border zone displaying a mean value of 60%
of fluorescence intensity of the center zone with a steep drop
between center and border zone. Using this information, images
were thresholded and two masks were created from Zinpyr1
fluorescence selecting areas above (center zone) and below 60%
(border zone) of average fluorescence intensity of Zinpyr1 of
the center of a plaque. These masks were used to create a
selection to measure S100 signal intensity inside the respective
zones of a plaque.
Protein Fractionation
To obtain P2 fractions from brain regions, the regions were
dissected, and 1 g tissue was homogenized in 10 ml Buffer
A containing protease inhibitor mixture (complete mini
EDTA free, Roche). Cell debris and nuclei were removed
by centrifugation at 3,200 rpm for 15 min resulting in
supernatant S1 (soluble fraction) and pellet P1 (membrane
associated fraction). Supernatants (S1) were centrifuged for
20 min at 11,400 rpm, resulting in S2 (soluble fraction)
and P2 (crude synaptosomal fraction). The resulting pellet
P2 was resuspended in homogenization buffer to measure
protein concentration by Bradford analysis followed by
western blotting.
Western Blotting
Proteins were separated by SDS-PAGE and blotted onto
Nitrocellulose membranes. Immunoreactivity was visualized
using HRP-conjugated secondary antibodies and the SuperSignal
detection system (Pierce, Upland, United States). Evaluation
of bands from Western blots was performed using ImageJ
v1.52c. Three independent experiments were performed,
and blots imaged using a MicroChemi Imaging System
from Biostep. The individual bands were selected, and
the integrated density was measured. All WB bands were
normalized to β-III-Tubulin and the ratios averaged and tested
for significance.
Statistics
Statistical analysis was performed using Microsoft Excel and
averages tested for significance using SPSS version 20. For
comparisons, analysis of variance (ANOVA) was performed
followed by post hoc tests for within group comparisons. Data are
shown as mean ± SEM. Significance levels were set at p < 0.05
(<0.05∗; <0.01∗∗; <0.001∗∗∗).
RESULTS AND DISCUSSION
S100A6 and S100B Show Brain Region
and Cell Type Specific Expression
To elucidate the origin of S100 proteins in brain parenchyma,
in a first set of experiments, we analyzed expression of
S100A6, S100A8, and S100B in vitro using 14 days old rat
hippocampal neuronal cultures. For S100A6 and S100B, we
detected immunoreactive signals mostly in astrocytes, but
also a weak signal in neurons (Supplementary Figure S1A).
S100A8 immunoreactive signals were found in neurons and glial
cells (Supplementary Figures S1B,C) revealed by co-staining
with a marker for astrocytes (Glial fibrillary acidic protein,
GFAP) and a marker for neurons (Microtubule-associated
protein 2, MAP2).
In order to investigate whether the results obtained in vitro
are representative for the in vivo situation, in the following set
of experiments we analyzed RNA lysates from different brain
regions (cortex, hippocampus, striatum, cerebellum) obtained
from adult wildtype (WT) C57BL/6 mice. mRNA expression
analysis for S100A6, S100A8, and S100B shows that the genes
are expressed in all brain regions. However, S100A6 shows the
highest expression in the cortex, and S100A8 in the cerebellum,
and S100B in the cortex and cerebellum (Figure 1A). mRNA
expression levels were confirmed on the protein level for S100B,
with the highest expression in the cerebellum (Figure 1B).
Based on this expression pattern, we selected the cortex
and cerebellum for subsequent immunohistochemical analysis to
identify protein expression and localization of S100A6, S100A8,
and S100B in these brain regions. S100A6 protein expression
was found in both brain regions (Figure 1C). In the cerebellum,
S100A6 seems to be enriched in the molecular layer. In contrast,
S100B is very specifically expressed in the Purkinje cells of
the cerebellum. Lower expression of S100B was detected in
other regions of the cerebellum and in the cortex (Figure 1E).
The expression of cerebellar S100B is well established in
the developing mouse cerebellum where it is proposed to
be involved in interactions with vimentin, to participate in
neurite extensions and to have neurotrophic activities (Hachem
et al., 2007). However, S100B-deficient mice exhibit normal
cerebellar development (Bluhm et al., 2015). On the other hand,
systematically elevated S100B levels during neurodevelopment
impair cerebellar oligodendrogenesis and myelination (Santos
et al., 2018). In the cortex, S100B protein expression is the highest
in layer IV. S100A8 protein expression in turn seems nearly
absent in neurons and glial in both cerebellar and cortical regions.
S100A8 signals almost exclusively originate from blood vessels,
either from endothelial cells forming the wall of blood vessels
or from protein in blood (Figure 1D). Thus, the expression
of S100A8 is different in dissociated cell culture from the
in vivo situation. Alternatively, altered expression may be due to
differences between rat used for cell culture, and mouse tissue
used for in vivo studies.
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FIGURE 1 | S100A6 and S100B show brain region and cell type specific expression in vivo. (A) RNA lysate was obtained from the cortex (ctx), hippocampus (hip),
striatum (str), and cerebellum (cer) of WT mice. Expression analysis for S100A6, S100A8, and S100B shows that the genes are expressed in all brain regions with
S100A6 showing the highest expression in the cortex, S100A8 in the cerebellum, and S100B in the cortex and cerebellum (n = 3) [one-way ANOVA,
FS100A6 = 8.319, pS100A6 = 0.008; FS100A8 = 40.602, pS100A8 = < 0.0001; FS100B = 9.043, pS100B = 0.006; Bonferroni post hoc analysis: S100A6: a significant
difference was detected between ctx and cer (p = 0.008). S100A8: a significant difference was detected between ctx and cer (p = 0.000254), hip and cer
(p = 0.000857), and str and cer (p = 0.000818). S100B: a significant difference was detected between hip and cer (p = 0.014), and str and cer (p = 0.01)]. (B) The
soluble protein fraction (S2) from protein lysate was obtained from the cortex (ctx), hippocampus (hip), striatum (str), and cerebellum (cer) of WT mice (n = 3). No
regional differences were detected on the protein level for S100A6 and S100A8 (one-way ANOVA, FS100A6 = 0.576, pS100A6 = 0.647; FS100A8 = 2.209,
pS100A8 = 0.165). A significant difference was detected for S100B (one-way ANOVA, FS100B = 7.118, pS100B = 0.012). Bonferroni post hoc analysis reveals a
significant higher level of S100B in cer compared to ctx (p = 0.0228), cer compared to hip (p = 0.04934), and cer vs. str (p = 0.03557). (C) Immunohistochemistry
performed on WT brain sections shows S100A6 protein expression in the cortex and cerebellum. In the cerebellum, S100A6 shows high expression in the molecular
layer (arrow). (D) S100A8 expression is absent in neurons and glial in both cerebellar and cortical regions. S100A8 signals originate from blood vessels. (E) S100B is
expressed in cortex and cerebellum. In the cerebellum, S100B is highly expressed specifically in the Purkinje cells (arrow). (C–E) Scale bars = 50 µm.
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FIGURE 2 | Altered localization of S100 proteins in the brain of AP23 mice. (A) APP23 mice were compared to controls at 3 moa and 15 moa. Representative
images of mouse prefrontal cortex are shown. A severe plaque-pathology was observed in 15 moa APP23 mice in this brain region. Plaques were visualized by
Zinpyr-1 staining and cell nuclei labeled using DAPI. (B) In 15 mao APP23 mice, S100A6 signals co-localize with Aβ plaques together with (C) S100A8, and
(D) S100B. Signal intensities have been adjusted to S100 fluorescence co-localizing with plaques leading to very low fluorescent signals in the surrounding tissue.
(E,F) Visualization of plaques using Thioflavin or Zinpyr1 reveals strong fluorescence in the center of plaques and weaker fluorescence in the border zone
corresponding to the aggregation state of Aβ. (F) S100A8 is significantly higher enriched in the center of Aβ aggregates (20–25 plaques each from n = 3 mice, t test,
p = 0.0077). S100A6 is found in the center and periphery of Aβ plaques (pS100A6 = 0.3896). In contrast, S100B is found in the center zone and is slightly enriched in
the border zone (pS100B = 0.1217). (A–D) scale bars = 300 µm, (E,F) = 50 µm.
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FIGURE 3 | Altered concentrations of S100A8 proteins in the brain of APP23 mice. Brain lysate was obtained from the cortex and cerebellum of control and APP23
mice at 3 and 15 moa. P2 fractions were used for analysis (n = 3). (A) Left, In Cortex, a statistically significant difference was found between APP and WT mice at
15 moa, but not a 3 moa. S100A8 levels were significantly higher in APP23 mice at 15 moa compared to WT mice (two-way ANOVA followed by Bonferroni post hoc
test, p = 0.0091). Right, S100B levels were higher in APP23 mice at each time-point with a significant difference between WT and APP23 mice at 15 moa (two-way
ANOVA followed by Bonferroni post hoc test, p = 0.0473). (B) Left, In Cerebellum, protein levels of S100A8 decrease during aging in the cortex of WT mice but not
in APP23 mice. However, two-way ANOVA analysis does not reveal significant differences. Right, Similarly, no significant time or genotype dependent differences
were observed for S100B in the cerebellum (two-way ANOVA).
Altered Localization of S100 Proteins in
the Brain of APP23 Mice
Given that a role of S100 proteins has been proposed in AD, we
next analyzed whether the expression and distribution of S100A6,
S100A8, and S100B is altered in APP23 mice compared to
controls before the onset of amyloid plaque pathology (3 months
of age, moa) and at old age with full amyloid plaque pathology
(15 moa). Pathology was confirmed by visualization of plaques in
brain sections of mice. Plaques were found in the hippocampus
and cortex of 15 months old APP23 mice, but in line with
the literature (Maier et al., 2015), no plaques were detected
in the cerebellum. The prefrontal cortex of mice was then
analyzed (Figure 2A).
In APP23 mice cortex (15 moa, plaque positive), S100A8
immunoreactive signals maintain their association with blood
vessels. However, in addition, S100A8 signal co-localizes with
Aβ plaques (Figure 2B). Similarly, S100A6 and S100B localize
to Aβ plaques (Figures 2C,D). Several methods exist to visualize
the plaques. Among them staining with Thioflavin is commonly
used. Thioflavin detects the presence of amyloid fibrils (Xue
et al., 2017). Cross-linked fibrils form the center of amyloid
plaques and increasing aggregation has been hypothesized to
originate from fibrils that radiate out from a center recruiting
Aβ monomers and oligomers (Drolle et al., 2014) that are
found in the periphery of a plaque. Therefore, staining with
Thioflavin results in a strong signal in the center of plaques and
weaker signals from the border zone. Like Thioflavin, Zinpyr-1,
a fluorophore labeling zinc associated with Aβ aggregates results
in a strong labeling of plaques. As zinc ion levels are elevated in
amyloid plaques (Stewart and Radford, 2017), and in particular
in β-sheets associated with fibrillar assemblies (Rambaran and
Serpell, 2008), also zinc staining shows higher fluorescence in
the center of plaques (Figures 2E,F). Analysis of the distribution
of S100 proteins within the center and border zone of plaques
revealed that S100A8 is significantly enriched in the center of Aβ
plaques. In contrast, S100B localizes to the center, but more so in
the border zone of plaques (Figure 2F). S100A6 is found both in
the center and border zone of plaques (Figure 2F).
Altered Concentrations of S100A8
Protein in the Brain of APP23 Mice
Given that changes in the expression of S100 family members
have been reported during aging in humans and WT mice
(Swindell et al., 2013), we next investigated if alterations on
protein level also occur for S100A8 and S100B, and whether
the differences found in WT animals are also observed in
APP23 mice. To that end, brain lysates were prepared and
sub-fractionated. To exclude the influence from blood vessels,
P2 (synaptosomal fractions) were used for the analysis. The
results show that aged WT mice have decreased protein levels of
S100A8 in the P2 fraction both from the cortex and cerebellum
(Figures 3A,B). However, this is not the case in the APP23
mice. A significantly higher level of S100A8 was found in the
in the P2 fraction from the cortex of APP23 mice compared
to WT at 15 moa (Figure 3A). The increased S100A8 levels in
the cortex of APP23 mice after development of AD pathology
are in line with the previous observed shift from S100A8 signals
mainly associated with blood vessels to the center of Aβ plaques.
S100B levels, on average, are higher in APP23 mice compared
to controls in both brain regions as early as 3 moa, with a
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FIGURE 4 | Effect of S100 proteins on Aβ42 aggregation. Fibril formation of
monomeric 5 µM Aβ42 (black, t1/2 = 0.8 h) in 50 mM Hepes (pH 7.4) with
1.1 mM CaCl2 at 37◦C under quiescent conditions in the presence of S100A6
(blue, t1/2 = 1.3 h), S100B (orange t1/2 = 2.2 h) and S100A8 (green,
t1/2 = 3.5 h), all at 15 µM. Plots represent averaged normalized intensity
curves, fitted to a secondary nucleation model, obtained from three
independent replicates for each of the tested conditions. t1/2, reaction half
times.
significant higher S100B level in the cortex of APP23 mice at
15 mao (Figure 3A).
Influence of S100 Proteins on Aβ
Aggregation
Considering the recent finding that S100B is a calcium-tuned
suppressor of Aβ42 aggregation (Cristóvão et al., 2018), and to
gain further mechanistic insights into the yet unclear roles of
S100 proteins near amyloid plaques, we next investigated if other
S100 proteins might play similar regulatory effects. For that, we
have conducted ThT monitored in vitro kinetic experiments of
amyloid formation, in which we tested the potential suppressing
effects of S100A6 and S100A8 over the aggregation of monomeric
Aβ42. Similar to what has been reported for S100B (Cristóvão
et al., 2018), the calcium-bound forms of S100A8 and S100A6
also delay Aβ42 aggregation (Figure 4). Indeed, the increased
half-times (t1/2) of the Aβ42 aggregation determined in the
presence of the analyzed S100 proteins reveal that S100A8 has
the strongest effect (∼7.5× increase), under the tested conditions.
For S100B this effect has been shown to result from a direct
physical interaction with Aβ42 (Cristóvão et al., 2018) and
at this stage we can only speculate that similar phenomena
might also be occurring for S100A6 and S100A8. In support
of this possibility is the evidence that the S100A8-containing
heterodimer calprotectin interacts with Aβ40, also influencing its
aggregation (Lee et al., 2018).
CONCLUSION
S100B, S100A8, and S100A6 are among the most prominent brain
expressed S100 proteins and are all upregulated upon traumatic
brain injury, aging, and neuronal damage. Understanding the
physiology of S100 proteins in the brain through a systematic
assessment of their relative distribution and expression levels
in healthy, aged and diseased states is a critical first step
to establish the molecular mechanisms through which these
important signaling molecules act on AD neurodegeneration.
Neuroinflammation is a well-established hallmark in AD, and
glia-neuronal interactions mediated through the chronic release
of glia-derived cytokines including Interleukin-1 and S100B are
postulated to be key for the neurodegeneration process (Griffin
et al., 1998). It is also emerging that early inflammation stages,
prior to plaque formation, encompass a number of released glial
mediators with the potential to regulate AD processes (Cuello,
2017). It is our contention that S100 proteins may play important
roles in the early AD stages and we have therefore in this work
interrogated about their location and distribution in the brain,
focusing on S100A8, S100A6, and S100B. Recent work from our
laboratories has shown that S100B has indeed novel chaperone-
like functions capable to mitigate the earliest stages of Aβ amyloid
aggregation and its toxicity (Cristóvão et al., 2018) and to buffer
neurotoxic zinc through its active chelation that impacts on
trace metal homeostasis (Hagmeyer et al., 2017). These findings
suggest that prior to pro-inflammatory and disease-aggravating
roles in later disease stages, S100 proteins may engage in new
protective activities related to amyloid aggregation processes,
which might be amenable to future pharmacological intervention
to mitigate AD progression.
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